REC-994
- Generic Name
- REC-994
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
REC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
- Associated Conditions
- -
- Associated Therapies
- -
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months
Recursion Pharmaceuticals advances drug discovery with AI/ML, delivering data to Bayer and initiating a joint oncology project. Bayer to beta-test LOWE for drug development. Recursion updates pipeline with seven clinical trial readouts expected within 18 months, leveraging its platform for high-throughput experiments and predictive modeling.
Recursion Provides Business Updates and Reports First Quarter 2024 Results
Recursion reported Q1 2024 updates, including Phase 2 clinical trials progress, BioHive-2 supercomputer benchmarking, and a Helix partnership for AI model training. They also announced financial results, with a net loss of $91.4M, and plans for future trials and collaborations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath